BiotechTube

Pembrolizumab

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous Squamous Cell Carcinoma of the Head and Neck

Conditions

Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer

Trial Timeline

Jun 28, 2022 → Jun 1, 2027

NCT ID
NCT05025813

About Pembrolizumab

Pembrolizumab is a phase 2 stage product being developed by Merck for Cutaneous Squamous Cell Carcinoma of the Head and Neck. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05025813. Target conditions include Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer.

What happened to similar drugs?

7 of 20 similar drugs in Cutaneous Squamous Cell Carcinoma of the Head and Neck were approved

Approved (7) Terminated (1) Active (12)
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
✅ONTAKEisaiApproved
✅MogamulizumabKyowa KirinApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved
✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT02083484Pre-clinicalCompleted
NCT07302347Phase 1/2Recruiting
NCT07089992Phase 2Recruiting
NCT07007273Phase 2Recruiting
NCT04569461Phase 2Withdrawn
NCT05815927Phase 3Recruiting
NCT05852223Phase 2Recruiting
NCT05879120Phase 2Withdrawn
NCT06004336Phase 2Recruiting
NCT05496036Phase 2Recruiting
NCT05131919Phase 2Active
NCT05197322Phase 2Recruiting
NCT05406713Phase 2Active
NCT05025813Phase 2Recruiting
NCT06413095Phase 1Completed
NCT05191472Phase 2Terminated
NCT05204160Phase 2Withdrawn
NCT04575961Phase 2Active
NCT04417166Phase 2Recruiting
NCT05188508Phase 2Recruiting

Competing Products

20 competing products in Cutaneous Squamous Cell Carcinoma of the Head and Neck

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
43
ONTAKEisaiApproved
43
E7777 9 mcg/kgEisaiPhase 3
40
ONTAKEisaiApproved
43
MogamulizumabKyowa KirinApproved
47
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
36
MogamulizumabKyowa KirinPhase 2
39
KW-0761 + VorinostatKyowa KirinPhase 3
40
EnzastaurinEli LillyPhase 2
35
Clopidogrel + TicagrelorAstraZenecaApproved
43
PembrolizumabMerckPhase 2
42
Comparator: vorinostatMerckPre-clinical
26
PembrolizumabMerckPhase 2
39
TR701 FAMerckPhase 2
35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 MonthsMerckPhase 2
35
Tulisokibart + PlaceboMerckPhase 2
39
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
35
Pembrolizumab + MogamulizumabMerckPhase 2
42
TR-701 FA + LinezolidMerckPhase 3
40
Pimasertib + DacarbazineMerckPhase 2
35